MicuRx Pharmaceuticals, Inc. has received U.S. FDA clearance for its Investigational New Drug (IND) application for MRX-5, enabling initiation of a Phase 2a clinical trial in patients with Mycobacterium abscessus pulmonary disease.
The clearance marks a key step forward for a program targeting a serious and difficult-to-treat non-tuberculous mycobacterial (NTM) infection with limited effective therapies.
Why M. abscessus Pulmonary Disease Needs Better Treatments?
M. abscessus pulmonary disease is associated with:
- High morbidity and progressive lung damage
- Long, complex multi-drug treatment regimens
- Poor tolerability and frequent adverse effects
- Suboptimal clinical outcomes
There are currently few effective oral options and no reliably curative therapies.
About MRX-5
MRX-5 is a novel, oral antibacterial agent designed to target NTM infections.
Preclinical and early clinical data show that MRX-5:
- Demonstrates potent activity against clinical isolates of M. abscessus
- Remains active against strains resistant to standard-of-care therapies
- Exhibits favorable pharmacokinetic properties
- Shows an encouraging safety profile
In 2024, the FDA granted Orphan Drug Designation to MRX-5 for the treatment of NTM infections.
Phase 2a Trial Overview
The Phase 2a study will be:
- Multicenter
- Conducted in the United States
- Enrolling adults with confirmed M. abscessus pulmonary disease
Primary objectives include evaluating:
- Safety and tolerability
- Preliminary efficacy
Results will guide subsequent development and later-stage trial design.
Company Perspective
Jerry (Zhiyue) Li, President of MicuRx, stated:
The FDA’s clearance of our IND for MRX-5 represents an important milestone for MicuRx and for patients suffering from M. abscessus pulmonary disease. This approval allows us to advance MRX-5 into a Phase 2a clinical trial to assess its safety and efficacy.
Expanding MicuRx’s Anti-Infective Pipeline
The IND clearance strengthens MicuRx’s clinical pipeline focused on:
- Drug-resistant bacterial infections
- Antimicrobial resistance challenges
- Hard-to-treat NTM diseases
MicuRx continues to leverage its expertise in medicinal chemistry and anti-infective drug development to address major global unmet medical needs.
